Dhuley J N, Naik S R
Pharmacology and Toxicology Division, Hindustan Antibiotics Limited, Pune, India.
J Ethnopharmacol. 1997 Apr;56(2):159-64. doi: 10.1016/s0378-8741(97)01524-9.
Rhinax, a herbal formulation, was investigated for its protective activity against CCl4-induced liver injury and survival in rats. Oral administration of Rhinax at a dose of 80 mg/kg significantly reduces the hepatotoxic effects of CCl4. It also significantly improves the survival of rats at a dose of 160 mg/kg. On the basis of these observations, we conclude that Rhinax possesses anti-hepatotoxic activity and that the observed activity may be due to the increased activity of cytochrome P450, thereby exerting an inhibitory effect on reductive pathways of CCl4.
对一种草药配方Rhinax进行了研究，以考察其对四氯化碳诱导的大鼠肝损伤的保护活性及对大鼠存活率的影响。以80毫克/千克的剂量口服Rhinax可显著降低四氯化碳的肝毒性作用。以160毫克/千克的剂量给药时，它还能显著提高大鼠的存活率。基于这些观察结果，我们得出结论，Rhinax具有抗肝毒性活性，且观察到的活性可能归因于细胞色素P450活性的增强，从而对四氯化碳的还原途径产生抑制作用。
